Clinical trial · Interventional
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake. However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing. It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy. The exact mechanisms underlying these differences is not yet known but might be caused by changes in vascularity. Therefore the vasculature is imaged with the help of a study specific Gallium-68-DOTA-(RGD)2 PET/CT scan and a CT perfusion scan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RGD PET/CT | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- HPV Negative tumours
- description
- Patients will receive four scans.
- interventionNames
- Combination Product: RGD PET/CT
- type
- ACTIVE_COMPARATOR
- label
- HPV positive tumours
- description
- Patients will receive four scans.
- interventionNames
- Combination Product: RGD PET/CT
Primary outcomes (6)
- measure
- Differences in RGD-tracer uptake between HPV positive and negative tumours
- timeFrame
- 1 month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Proven squamous cell carcinoma of the oropharynx * p-16 immunohistochemistry analysis * Tumour lesion of at least 1.0 cm in diameter * Planned chemoradiotherapy as primary treatment * Ability to provide written informed consent Exclusion Criteria: * Contra-indications for PET * Contra-indications for administration of iodine-containing contrast agents * Other serious illness that can affect the scans
References
Publications (0)
Data not yet available